Key result
ANGPTL3 inhibition lowers atherogenic lipids independently of LDLR, but lacks cardiovascular outcome data.
Why the study?
Many patients retain residual cardiovascular risk from elevated triglyceride-rich lipoproteins and remnant cholesterol despite achieving LDL-C targets with statins and PCSK9 inhibitors. ANGPTL3 has emerged as a mechanistically distinct target that lowers triglycerides, LDL-C, and HDL-C independently of the LDL receptor.
Does pharmacological inhibition of ANGPTL3 improve lipid biomarkers and reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease or dyslipidemia?
Does pharmacological inhibition of ANGPTL3 improve lipid biomarkers and reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease or dyslipidemia?
Answers are grounded in this paper and cite their sources.
Pharmacological inhibition of ANGPTL3 across multiple therapeutic modalities lowers triglycerides, LDL-C, and apoB independently of the LDL receptor, though human data remain limited to lipid biomarkers in small, short trials with varying hepatic safety profiles and no proven cardiovascular event reduction yet.
Atherosclerotic cardiovascular disease remains the leading cause of death worldwide despite the widespread use of statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A substantial fraction of treated patients retain elevated triglyceride-rich lipoproteins and remnant cholesterol after low-density lipoprotein cholesterol (LDL-C) targets have been met, which has been proposed to contribute to residual cardiovascular risk; however, lowering triglycerides alone has not reliably reduced cardiovascular events, and benefit appears more closely tied to the reduction in apolipoprotein B (apoB)-containing particles. Angiopoietin-like protein 3 (ANGPTL3), a hepatically secreted regulator of lipoprotein lipase and endothelial lipase, has emerged as a mechanistically distinct target that lowers triglycerides, LDL-C, and high-density lipoprotein cholesterol (HDL-C) independently of the LDL receptor (LDLR). This narrative review, based on a structured PubMed/MEDLINE search, synthesizes the structural biology of ANGPTL3, compares ANGPTL3 with PCSK9, ANGPTL4, apolipoprotein C-III (APOC3) and other lipid-lowering therapies, summarizes the preclinical and clinical evidence on its pharmacological inhibition, including the effects of each agent on LDL-C, triglycerides, apoB and non-HDL-C, and discusses the limitations of that evidence and of the review itself. Loss-of-function variants in ANGPTL3 are associated with a lower risk of coronary artery disease in large population cohorts. Pharmacological inhibition has since been tested with several independent modalities, which lower atherogenic lipids but have not been shown to reduce cardiovascular events: monoclonal antibodies (evinacumab, SHR-1918), antisense oligonucleotides (vupanorsen), small interfering RNAs (zodasiran, solbinsiran), and, most recently, in vivo CRISPR-Cas9 gene editing (CTX310). In humans, the evidence for pharmacological inhibition is limited to lipid biomarkers in generally small and short trials; reductions in apoB are consistently smaller than reductions in triglycerides, and evidence of plaque regression derives from animal models only. Each modality carries a distinct efficacy and hepatic safety profile, a divergence (hepatic fat increased with the antisense agent vupanorsen but not with the siRNA agents studied) whose cause—platform chemistry, depth of knockdown, study population or ANGPTL3 biology itself—cannot be determined from the available cross-trial comparisons. We conclude with concrete recommendations for cardiovascular outcome trials, prospective hepatic-fat monitoring, and rational combination strategies with LDLR-dependent agents.
No takes yet. Share an insight, caveat, or question.
Blagov et al. (2026) conducted a review in Atherosclerotic cardiovascular disease and dyslipidemia. Pharmacological ANGPTL3 inhibition (monoclonal antibodies, antisense oligonucleotides, siRNAs, CRISPR-Cas9 gene editing) vs. PCSK9, ANGPTL4, APOC3, and other lipid-lowering therapies was evaluated on Lipid biomarkers (LDL-C, triglycerides, apoB, non-HDL-C, HDL-C) and cardiovascular events. Pharmacological ANGPTL3 inhibition lowers triglycerides, LDL-C, and apoB independently of LDLR across multiple modalities, though clinical evidence has not yet shown reduced cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: